Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Feb;19(2):76-77.
doi: 10.1038/s41584-022-00892-3.

COVID-19 vaccination in individuals with inflammatory rheumatic diseases

Alla Skapenko  1 , Hendrik Schulze-Koops  2
Affiliations

COVID-19 vaccination in individuals with inflammatory rheumatic diseases

Alla Skapenko et al. Nat Rev Rheumatol. 2023 Feb.

Abstract

Since the start of the SARS-CoV-2 vaccination campaign, our knowledge of the effects of vaccines in people with inflammatory rheumatic diseases has remained incomplete. In particular, the effects of immunomodulatory therapies on vaccine success are poorly understood. Three notable papers from the past year have helped to fill these knowledge gaps.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

References

    1. Geisen UM, et al. Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort. Ann. Rheum. Dis. 2021;80:306–311. doi: 10.1136/annrheumdis-2021-220272. - DOI - PMC - PubMed
    1. Sattui SE, et al. Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey. RMD Open. 2021;7:e001814. doi: 10.1136/rmdopen-2021-001814. - DOI - PMC - PubMed
    1. Furer V, et al. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study. Ann. Rheum. Dis. 2021;80:1330–1338. doi: 10.1136/annrheumdis-2021-220647. - DOI - PubMed
    1. Sieiro Santos C, et al. Immune responses to mRNA vaccines against SARS-CoV-2 in patients with immune-mediated inflammatory rheumatic diseases. RMD Open. 2022;8:e001898. doi: 10.1136/rmdopen-2021-001898. - DOI - PMC - PubMed
    1. Schulze-Koops H, Krueger K, Vallbracht I, Hasseli R, Skapenko A. Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab. Ann. Rheum. Dis. 2021;80:e67. doi: 10.1136/annrheumdis-2020-218075. - DOI - PubMed

Publication types

Substances